1.4M euros have been granted by ZonMw to the consortium to carry on the development of pan-corona antiviral initiated in the predecessor project PanCoroNed. The consortium is composed of a broad coalition of knowledge institutions and private stakeholders, including the Institute for Molecules and Materials (IMM) of Radboud University and

The funding will be dedicated to developing our broad-spectrum pan-flavi antiviral drug PTL- 244 to clinical phase II stage for the most common flavivirus: dengue. Dengue is endemic in more than 100 countries (a.o. Singapore, Brazil, Thailand and India) and 400 million people get infected annually. Currently, there is no